PRL3-zumab, a first-in-class humanized antibody for cancer therapy

Novel, tumor-specific drugs are urgently needed for a breakthrough in cancer therapy. Herein, we generated a first-in-class humanized antibody (PRL3-zumab) against PRL-3, an intracellular tumor-associated phosphatase upregulated in multiple human cancers, for unconventional cancer immunotherapies. W...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:JCI Insight
Auteurs principaux: Thura, Min, Al-Aidaroos, Abdul Qader Omer, Yong, Wei Peng, Kono, Koji, Gupta, Abhishek, Lin, You Bin, Mimura, Kousaku, Thiery, Jean Paul, Goh, Boon Cher, Tan, Patrick, Soo, Ross, Hong, Cheng William, Wang, Lingzhi, Lin, Suling Joyce, Chen, Elya, Rha, Sun Young, Chung, Hyun Cheol, Li, Jie, Nandi, Sayantani, Yuen, Hiu Fung, Zhang, Shu-Dong, Guan, Yeoh Khay, So, Jimmy, Zeng, Qi
Format: Artigo
Langue:Inglês
Publié: American Society for Clinical Investigation 2016
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5033845/
https://ncbi.nlm.nih.gov/pubmed/27699276
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.87607
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires